Atopic Dermatitis

Due to a small increase in eczematous dermatitis, older adults taking antihypertensive drugs should be monitored and this possibility considered when assessing for eczema, according to a study.

Johnson & Johnson will pay $850 million to acquire the biotechnology company Proteologix Inc., the company announced in a press release.

Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.

Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company announced in a press release.

Young infants with lower lung function and impaired skin barrier function experienced greater risks for developing asthma by age 3 years, according to a study published in Allergy.

Technoderma Medicines has dosed its first patients in its phase 2a clinical trial of topical TDM-180935 ointment for the treatment of atopic dermatitis, the company announced in a press release.

Stigma has a major impact on mental health and quality of life for pediatric patients with chronic skin diseases, according to a study.

Eli Lilly and Company announced a net revenue increase of 26% in the first quarter of 2024 and the resubmission of its biologic license application for lebrikizumab for the treatment of atopic dermatitis, according to a press release.

SelectION announced positive results from its first-in-human phase 1b trial of its lead compound, a selectively-optimized peptide, for the treatment of patients with atopic dermatitis, according to a company press release.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.